Long-term efficacy and safety of difelikefalin in moderate-to-severe pruritus in Japanese hemodialysis patients: a 52-week open-label extension period of a phase 3 trial

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Long-term efficacy and safety of difelikefalin in moderate-to-severe pruritus in Japanese hemodialysis patients: a 52-week open-label extension period of a phase 3 trial ; volume:10 ; number:1 ; day:19 ; month:7 ; year:2024 ; pages:1-13 ; date:12.2024
Renal replacement therapy ; 10, Heft 1 (19.7.2024), 1-13, 12.2024

Creator
Narita, Ichiei
Tsubakihara, Yoshiharu
Takahashi, Naoko
Ebata, Toshiya
Uchiyama, Takuma
Marumo, Masaya
Okamura, Shota
Gejyo, Fumitake
Contributor
SpringerLink (Online service)

DOI
10.1186/s41100-024-00557-9
URN
urn:nbn:de:101:1-2410052130360.050141235300
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Narita, Ichiei
  • Tsubakihara, Yoshiharu
  • Takahashi, Naoko
  • Ebata, Toshiya
  • Uchiyama, Takuma
  • Marumo, Masaya
  • Okamura, Shota
  • Gejyo, Fumitake
  • SpringerLink (Online service)

Other Objects (12)

Pruritus in hemodialysis patients

Pruritus in hemodialysis patients

Multidimensional pruritus assessment in hemodialysis patients

Multidimensional pruritus assessment in hemodialysis patients

Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2

Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2

Association Between Serum Aluminum Level and Uremic Pruritus in Hemodialysis Patients

Association Between Serum Aluminum Level and Uremic Pruritus in Hemodialysis Patients

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study

Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study

Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study

Prevalence of pruritus associated with hemodialysis and its association with sleep quality among hemodialysis patients: a multicenter study

Prevalence of pruritus associated with hemodialysis and its association with sleep quality among hemodialysis patients: a multicenter study

Impact of pruritus in patients undergoing hemodialysis in Italy: a patient-based survey

Impact of pruritus in patients undergoing hemodialysis in Italy: a patient-based survey

Pruritus Ani

Kapitel

Pruritus Ani

Chronischer Pruritus

Chronischer Pruritus

Related objects